Thomas R. Nirschl

2.6k total citations · 1 hit paper
33 papers, 1.4k citations indexed

About

Thomas R. Nirschl is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Thomas R. Nirschl has authored 33 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 21 papers in Immunology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Thomas R. Nirschl's work include Cancer Immunotherapy and Biomarkers (22 papers), Immunotherapy and Immune Responses (11 papers) and Prostate Cancer Treatment and Research (8 papers). Thomas R. Nirschl is often cited by papers focused on Cancer Immunotherapy and Biomarkers (22 papers), Immunotherapy and Immune Responses (11 papers) and Prostate Cancer Treatment and Research (8 papers). Thomas R. Nirschl collaborates with scholars based in United States, Taiwan and China. Thomas R. Nirschl's co-authors include Charles G. Drake, Christina M. Kochel, Christopher J. Nirschl, Brian J. Francica, Esteban Velarde, Andrew B. Sharabi, Theodore L. DeWeese, Robert A. Anders, Alan K. Meeker and Ali Ghasemzadeh and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Thomas R. Nirschl

31 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

2014 510 citations Andrew B. Sharabi, Christopher J. Nirschl et al. Cancer Immunology Research profile →

Peers

Countries citing papers authored by Thomas R. Nirschl

Since Specialization

Citations

This map shows the geographic impact of Thomas R. Nirschl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas R. Nirschl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas R. Nirschl more than expected).

Fields of papers citing papers by Thomas R. Nirschl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas R. Nirschl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas R. Nirschl. The network helps show where Thomas R. Nirschl may publish in the future.

Co-authorship network of co-authors of Thomas R. Nirschl

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas R. Nirschl. A scholar is included among the top collaborators of Thomas R. Nirschl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas R. Nirschl. Thomas R. Nirschl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity 2025 ·Cancer Research Communications ·Roy Elias, Thomas R. Nirschl, Michael E. Rezaee, (unknown), (unknown), Joseph Cheaib, Ridwan Alam, Sunil Patel, Yuezhou Jing, Mohamad E. Allaf, David McKean, Alison P. Klein, Elana J. Fertig, Ezra Baraban, Yasser Ged, Srinivasan Yegnasubramanian, Nirmish Singla	1
2	Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma 2024 ·Scientific Reports ·Nirmish Singla, Thomas R. Nirschl, Aleksandar Obradović, Eugene Shenderov, Kara A. Lombardo, Xiaopu Liu, Alice Pons, Jelani C. Zarif, Steven P. Rowe, Bruce J. Trock, Hans J. Hammers, Trinity J. Bivalacqua, Phillip M. Pierorazio, Julie S. Deutsch, Tamara L. Lotan, Janis M. Taube, Yasser Ged, Michael A. Gorin, Mohamad E. Allaf, Charles G. Drake	4
3	Barcoding intracellular reverse transcription enables high-throughput phenotype-coupled T cell receptor analyses 2023 ·Cell Reports Methods ·(unknown), Janelle M. Montagne, Thomas R. Nirschl, Emily F. Davis-Marcisak, (unknown), Amanda L. Huff, (unknown), Julie M. Nauroth, Thatcher Heumann, Jelani C. Zarif, Elizabeth M. Jaffee, Nilo Azad, Elana J. Fertig, Neeha Zaidi, H. Benjamin Larman	1
4	Profiling serum antibodies with a pan allergen phage library identifies key wheat allergy epitopes 2021 ·Nature Communications ·Daniel R. Monaco, Brandon Sie, Thomas R. Nirschl, (unknown), Hugh A. Sampson, Anna Nowak‐Węgrzyn, Robert A. Wood, Robert G. Hamilton, Pamela A. Frischmeyer‐Guerrerio, H. Benjamin Larman	34
5	TGM4: an immunogenic prostate-restricted antigen 2021 ·Journal for ImmunoTherapy of Cancer ·Zoila A. Lopez‐Bujanda, Aleksandar Obradović, Thomas R. Nirschl, Laura Crowley, (unknown), (unknown), Timothy J. O’Donnell, Uri Laserson, Jelani C. Zarif, Ran Reshef, Tiezheng Yuan, (unknown), Emmanuel S. Antonarakis, Michael C. Haffner, H. Benjamin Larman, Michael M. Shen, Pawel Muranski, Charles G. Drake	16
6	Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma 2021 ·European Urology Oncology ·Michael A. Gorin, Hiten D. Patel, Steven P. Rowe, Noah M. Hahn, Hans J. Hammers, Alice Pons, Bruce J. Trock, Phillip M. Pierorazio, Thomas R. Nirschl, Daniela C. Salles, Julie E. Stein, Tamara L. Lotan, Janis M. Taube, Charles G. Drake, Mohamad E. Allaf	40
7	T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer 2020 ·Clinical Cancer Research ·Aleksandar Obradović, Matthew C. Dallos, Marianna Zahurak, Alan W. Partin, Edward M. Schaeffer, Ashley E. Ross, Mohamad E. Allaf, Thomas R. Nirschl, David Liu, Carolyn G. Chapman, Tanya O’Neal, Haiyi Cao, Jennifer N. Durham, Güneş Güner, Javier Baena-Del Valle, Onur Ertunç, Angelo M. De Marzo, Emmanuel S. Antonarakis, Charles G. Drake	73
8	A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target 2020 ·Journal of Clinical Investigation ·Zachary T. Freeman, Thomas R. Nirschl, Daniel H. Hovelson, Robert J. Johnston, John Engelhardt, Mark Selby, Christina M. Kochel, Ruth Y. Lan, (unknown), Ali Ghasemzadeh, Anuj Gupta, Alyza Skaist, Sarah J. Wheelan, Hui Jiang, Alexander T. Pearson, Linda A. Snyder, Alan J. Korman, Scott A. Tomlins, Srinivasan Yegnasubramanian, Charles G. Drake	68
9	Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer 2019 ·European Urology Oncology ·Max Kates, Thomas R. Nirschl, Alex S. Baras, Nikolai A. Sopko, Noah M. Hahn, Xiaoping Su, Jiexin Zhang, Christina M. Kochel, Woonyoung Choi, David J. McConkey, Charles G. Drake, Trinity J. Bivalacqua	7
10	Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition 2019 ·Journal for ImmunoTherapy of Cancer ·Wendy Mao, Ali Ghasemzadeh, Zachary T. Freeman, Aleksandar Obradović, Matthew G. Chaimowitz, Thomas R. Nirschl, (unknown), Srinivasan Yegnasubramanian, Charles G. Drake	50
11	Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer 2017 ·Cancer Immunology Research ·Max Kates, Thomas R. Nirschl, Nikolai A. Sopko, Hotaka Matsui, Christina M. Kochel, Leonardo Oliveira Reis, George J. Netto, Mohammad Obaidul Hoque, Noah M. Hahn, David J. McConkey, Alex S. Baras, Charles G. Drake, Trinity J. Bivalacqua	56
12	Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment 2017 ·Cancer Immunology Research ·Yuki Muroyama, Thomas R. Nirschl, Christina M. Kochel, Zoila A. Lopez‐Bujanda, Debebe Theodros, Wendy Mao, (unknown), Ali Ghasemzadeh, Ariel E. Marciscano, Esteban Velarde, Ada Tam, Christopher J. Thoburn, (unknown), Alan K. Meeker, Robert A. Anders, Drew M. Pardoll, Charles G. Drake	166
13	Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model 2017 ·Prostate Cancer and Prostatic Diseases ·Ying‐Chun Shen, Ali Ghasemzadeh, Christina M. Kochel, Thomas R. Nirschl, Brian J. Francica, Zoila A. Lopez‐Bujanda, (unknown), Ada Tam, Robert A. Anders, Mark Selby, Alan J. Korman, Charles G. Drake	41
14	Stereotactic radiotherapy increases functionally suppressive regulatory T cells in the tumor microenvironment 2017 ·The Journal of Immunology ·Yuki Muroyama, Thomas R. Nirschl, Christina M. Kochel, (unknown), Debebe Theodros, Wendy L. Mao, (unknown), Ali Ghasemzadeh, Ariel E. Marciscano, Esteban Velarde, Ada Tam, Christopher J. Thoburn, (unknown), Alan K. Meeker, Robert A. Anders, Drew M. Pardoll, Charles G. Drake	5
15	Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC). 2017 ·Journal of Clinical Oncology ·Karim Boudadi, Daniel L. Suzman, Brandon Luber, Hao Wang, John L. Silberstein, Rana Sullivan, Donna Dowling, Rana Harb, Thomas R. Nirschl, Ryan Dittamore, Michael A. Carducci, Mario A. Eisenberger, Michael C. Haffner, Alan K. Meeker, James R. Eshleman, Jun Luo, Charles G. Drake, Emmanuel S. Antonarakis	24
16	Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance 2015 ·Prostate Cancer and Prostatic Diseases ·Allison Martin, Thomas R. Nirschl, Christopher J. Nirschl, Brian J. Francica, Christina M. Kochel, Adrie van Bokhoven, Alan K. Meeker, M. Scott Lucia, Robert A. Anders, Angelo M. De Marzo, Charles G. Drake	142
17	Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas 2015 ·Journal of Neuro-Oncology ·Jian Campian, Xiaobu Ye, Douglas E. Gladstone, Prakash Ambady, Thomas R. Nirschl, Ivan Borrello, Marc G. Golightly, Karen E. King, Matthias Holdhoff, Judith E. Karp, Charles G. Drake, Stuart A. Grossman	36
18	Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen breakdown → 2014 ·Cancer Immunology Research ·Andrew B. Sharabi, Christopher J. Nirschl, Christina M. Kochel, Thomas R. Nirschl, Brian J. Francica, Esteban Velarde, Theodore L. DeWeese, Charles G. Drake	510
19	Sustained CD4⁺T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide 2014 ·OncoImmunology ·Susannah G. Ellsworth, Ani Sarkis Balmanoukian, Ferdynand Kos, Christopher J. Nirschl, Thomas R. Nirschl, Stuart A. Grossman, Leo Luznik, Charles G. Drake	58
20	Role of Radiation Therapy in Inducing Antigen Specific Antitumor Immune Responses When Combined With Anti-PD1 Checkpoint Blockade: Mechanism and Clinical Implications 2014 ·International Journal of Radiation OncologyBiologyPhysics ·Andrew B. Sharabi, Christopher J. Nirschl, (unknown), Thomas R. Nirschl, Brian J. Francica, Angela Alme, Esteban Velarde, (unknown), Charles G. Drake	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact